STEMPOINT CAPITAL LP
13F Reported Value
ⓘ$580.5M
incl. option notional
Equity Holdings
ⓘ$577.9M
Option Notional
ⓘ$2.6M
$747,500 puts / $1.9M calls
Holdings
84
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
STEMPOINT CAPITAL LP disclosed 84 positions worth $580.5M in its Form 13F-HR for Q2 2026 — $577.9M in common stock plus $2.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $TNGX (Tango Therapeutics, Inc.) at 6.6% of the equity portfolio, followed by $ABVX and $RVMD. During the quarter the fund opened 34 new positions and exited 32 — including a new stake in $KNSA and a full exit from $SNDX. The portfolio is most concentrated in Healthcare (98.8% of disclosed assets). All figures are sourced directly from STEMPOINT CAPITAL LP’s Form 13F-HR filing with the SEC under CIK 1952142.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 17.6#2,823
Quality
$38.2M1,223,019 sh - —
Quality
$37.8M283,657 sh - —
Quality
$30.0M159,943 sh - —
Quality
$28.7M1,565,913 sh - —
Quality
$20.2M632,754 sh - 22.6
Quality
$19.6M200,851 sh - —
Quality
$17.6M346,914 sh - —
Quality
$16.3M602,686 sh - —
Quality
$15.8M1,064,200 sh - —
Quality
$13.8M602,798 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Tango Therapeutics, Inc.$TNGX | 17.6#2,823 | $38.2M | 1,223,019 |
 Abivax S.A.$ABVX | — | $37.8M | 283,657 |
 Revolution Medicines, Inc.$RVMD | — | $30.0M | 159,943 |
 Erasca, Inc.$ERAS | — | $28.7M | 1,565,913 |
 Tyra Biosciences, Inc.$TYRA | — | $20.2M | 632,754 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $19.6M | 200,851 |
 Enliven Therapeutics, Inc.$ELVN | — | $17.6M | 346,914 |
 Mineralys Therapeutics, Inc.$MLYS | — | $16.3M | 602,686 |
 Biohaven Ltd.$BHVN | — | $15.8M | 1,064,200 |
 Surrozen, Inc./DE$SRZN | — | $13.8M | 602,798 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of STEMPOINT CAPITAL LP's 84 positions.
Showing top 10 of 84 holdings.
Sector Allocation
Healthcare
$571.2M
Technology
$4.8M
Other
$1.8M
Full Holdings — STEMPOINT CAPITAL LP (Q2 2026)
All 84 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TNGX | Tango Therapeutics, Inc. | $38.2M | 6.6% | +509% | 17.6 |
| 2 | $ABVX | Abivax S.A. | $37.8M | 6.5% | -10% | — |
| 3 | $RVMD | Revolution Medicines, Inc. | $30.0M | 5.2% | -43% | — |
| 4 | $ERAS | Erasca, Inc. | $28.7M | 5.0% | +553% | — |
| 5 | $TYRA | Tyra Biosciences, Inc. | $20.2M | 3.5% | +228% | — |
| 6 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $19.6M | 3.4% | +135% | 22.6 |
| 7 | $ELVN | Enliven Therapeutics, Inc. | $17.6M | 3.0% | -5% | — |
| 8 | $MLYS | Mineralys Therapeutics, Inc. | $16.3M | 2.8% | +13% | — |
| 9 | $BHVN | Biohaven Ltd. | $15.8M | 2.7% | -33% | — |
| 10 | $SRZN | Surrozen, Inc./DE | $13.8M | 2.4% | +208% | — |
| 11 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $13.4M | 2.3% | NEW | — |
| 12 |  $SRRK | Scholar Rock Holding Corp | $13.2M | 2.3% | -77% | — |
| 13 |  $ALKS | Alkermes plc. | $13.0M | 2.3% | +208% | — |
| 14 |  $TRAX | First Tracks Biotherapeutics, Inc. | $12.5M | 2.2% | NEW | — |
| 15 |  $PRAX | Praxis Precision Medicines, Inc. | $12.5M | 2.2% | -34% | — |
| 16 |  $ROIV | Roivant Sciences Ltd. | $12.3M | 2.1% | -10% | — |
| 17 |  $BIOA | BioAge Labs, Inc. | $11.4M | 2.0% | +37% | 26.8 |
| 18 |  $CGON | CG Oncology, Inc. | $11.3M | 2.0% | -23% | 27 |
| 19 |  $ORKA | Oruka Therapeutics, Inc. | $11.1M | 1.9% | NEW | — |
| 20 |  $IMVT | Immunovant, Inc. | $10.7M | 1.8% | -63% | — |
| 21 |  $CELC | Celcuity Inc. | $10.3M | 1.8% | +64% | — |
| 22 |  $RLMD | RELMADA THERAPEUTICS, INC. | $10.1M | 1.8% | +144% | — |
| 23 |  $CLYM | Climb Bio, Inc. | $9.7M | 1.7% | NEW | — |
| 24 |  $SYRE | Spyre Therapeutics, Inc. | $9.5M | 1.6% | -36% | — |
| 25 |  $ZURA | Zura Bio Ltd | $8.1M | 1.4% | +82% | — |
| 26 |  $IFRX | InflaRx N.V. | $7.2M | 1.3% | NEW | — |
| 27 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $6.9M | 1.2% | -43% | 8.7 |
| 28 |  $CLDX | Celldex Therapeutics, Inc. | $6.6M | 1.1% | -30% | 8.4 |
| 29 |  $OVID | Ovid Therapeutics Inc. | $6.5M | 1.1% | NEW | 26.4 |
| 30 |  $EQ | Equillium, Inc. | $6.5M | 1.1% | NEW | 11.7 |
| 31 |  $DFTX | Definium Therapeutics, Inc. | $6.5M | 1.1% | -58% | — |
| 32 |  $CYTK | CYTOKINETICS INC | $6.4M | 1.1% | -42% | 28.1 |
| 33 |  $DMRA | Damora Therapeutics, Inc. | $5.6M | 1.0% | NEW | — |
| 34 |  $IVA | Inventiva S.A. | $5.4M | 0.9% | NEW | — |
| 35 |  $IPSC | Century Therapeutics, Inc. | $5.3M | 0.9% | NEW | 33.5 |
| 36 |  $AURA | Aura Biosciences, Inc. | $5.1M | 0.9% | NEW | — |
| 37 |  $EYPT | EyePoint, Inc. | $4.8M | 0.8% | -58% | 3.5 |
| 38 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $4.7M | 0.8% | -8% | 41.5 |
| 39 |  $WHWK | Whitehawk Therapeutics, Inc. | $4.7M | 0.8% | +9% | 26.4 |
| 40 |  $XENE | Xenon Pharmaceuticals Inc. | $4.6M | 0.8% | -46% | 24 |
| 41 |  $QURE | uniQure N.V. | $4.1M | 0.7% | +13% | — |
| 42 |  $CMPS | COMPASS Pathways plc | $4.0M | 0.7% | NEW | — |
| 43 |  $AVLN | Avalyn Pharma Inc. | $3.9M | 0.7% | NEW | — |
| 44 |  $MPLT | MapLight Therapeutics, Inc. | $3.8M | 0.7% | +7% | — |
| 45 |  $ALMS | ALUMIS INC. | $3.8M | 0.7% | -41% | 7.1 |
| 46 |  $AXSM | Axsome Therapeutics, Inc. | $3.8M | 0.7% | NEW | 40.8 |
| 47 |  $GLUE | Monte Rosa Therapeutics, Inc. | $3.7M | 0.6% | NEW | 30.3 |
| 48 |  $ACAD | ACADIA PHARMACEUTICALS INC | $3.6M | 0.6% | -41% | 67.8 |
| 49 |  $SLDB | Solid Biosciences Inc. | $3.6M | 0.6% | +84% | — |
| 50 |  $PSNL | Personalis, Inc. | $3.3M | 0.6% | NEW | 11.3 |
| 51 |  $CBIO | CRESCENT BIOPHARMA, INC. | $3.3M | 0.6% | NEW | 9.6 |
| 52 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $3.2M | 0.6% | NEW | 38.7 |
| 53 |  $KOD | Kodiak Sciences Inc. | $3.0M | 0.5% | NEW | — |
| 54 |  $PHVS | Pharvaris N.V. | $2.8M | 0.5% | -7% | — |
| 55 |  $MNPR | Monopar Therapeutics | $2.8M | 0.5% | NEW | — |
| 56 |  $RAPP | Rapport Therapeutics, Inc. | $2.8M | 0.5% | NEW | — |
| 57 |  $NAMS | NewAmsterdam Pharma Co N.V. | $2.6M | 0.5% | -57% | — |
| 58 |  $SION | Sionna Therapeutics, Inc. | $2.6M | 0.5% | +63% | — |
| 59 |  $ARQT | Arcutis Biotherapeutics, Inc. | $2.6M | 0.5% | -76% | 62.9 |
| 60 |  $CCCC | C4 Therapeutics, Inc. | $2.4M | 0.4% | +16% | 18.2 |
| 61 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $2.2M | 0.4% | +551% | — |
| 62 |  $CUE | Cue Biopharma, Inc. | $2.1M | 0.4% | NEW | 28.9 |
| 63 |  $GPCR | Structure Therapeutics Inc. | $2.0M | 0.3% | -81% | — |
| 64 |  $PTGX | Protagonist Therapeutics, Inc | $2.0M | 0.3% | -78% | 59.4 |
| 65 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $1.8M | 0.3% | -44% | — |
| 66 |  $BDSX | BIODESIX INC | $1.6M | 0.3% | -0% | 35 |
| 67 |  $TENX | TENAX THERAPEUTICS, INC. | $1.4M | 0.2% | -49% | — |
| 68 |  $SABS | SAB Biotherapeutics, Inc. | $1.3M | 0.2% | -9% | — |
| 69 |  $CALC | CalciMedica, Inc. | $1.2M | 0.2% | NEW | — |
| 70 |  $LBRX | LB PHARMACEUTICALS INC | $1.0M | 0.2% | -36% | — |
| 71 |  $CLRB | Cellectar Biosciences, Inc. | $986,728 | 0.2% | NEW | — |
| 72 | $PSNLCALL | Personalis, Inc. | $810,750 | — | NEW | 11.3 |
| 73 |  $PRQR | ProQR Therapeutics N.V. | $801,760 | 0.1% | NEW | — |
| 74 | $BHVNCALL | Biohaven Ltd. | $525,000 | — | NEW | — |
| 75 | — | SPDR SERIES TRUST - ST STR SP BIOT | $400,000 | — | NEW | — |
| 76 |  $AZNCALL | ASTRAZENECA PLC | $180,000 | — | NEW | — |
| 77 | — | SPDR SERIES TRUST - ST STR SP BIOT | $178,000 | — | +167% | — |
| 78 | $TNGXCALL | Tango Therapeutics, Inc. | $175,000 | — | NEW | 17.6 |
| 79 | $RVMDPUT | Revolution Medicines, Inc. | $127,500 | — | -70% | — |
| 80 | $ERASPUT | Erasca, Inc. | $90,000 | — | NEW | — |
| 81 | — | ARK ETF TR - GENOMIC REV ETF | $75,000 | — | NEW | — |
| 82 | $ROIVPUT | Roivant Sciences Ltd. | $40,000 | — | NEW | — |
| 83 |  $VTGN | Vistagen Therapeutics, Inc. | $17,276 | 0.0% | +0% | — |
| 84 |  $AMGNPUT | AMGEN INC | $15,000 | — | NEW | 79.2 |
New Positions (34)
$KNSA Kiniksa Pharmaceuticals International, plc$13.4M$TRAX First Tracks Biotherapeutics, Inc.$12.5M$ORKA Oruka Therapeutics, Inc.$11.1M$CLYM Climb Bio, Inc.$9.7M$IFRX InflaRx N.V.$7.2M$OVID Ovid Therapeutics Inc.$6.5M$EQ Equillium, Inc.$6.5M$DMRA Damora Therapeutics, Inc.$5.6M$IVA Inventiva S.A.$5.4M$IPSC Century Therapeutics, Inc.$5.3M$AURA Aura Biosciences, Inc.$5.1M$CMPS COMPASS Pathways plc$4.0M$AVLN Avalyn Pharma Inc.$3.9M$AXSM Axsome Therapeutics, Inc.$3.8M$GLUE Monte Rosa Therapeutics, Inc.$3.7MExited Positions (32)
$SNDX Syndax Pharmaceuticals Inc
$MBX MBX Biosciences, Inc.
$BSXCALL BOSTON SCIENTIFIC CORP
$DYN Dyne Therapeutics, Inc.
$EWTX Edgewise Therapeutics, Inc.
$DNLI Denali Therapeutics Inc.
$TERNCALL Terns Pharmaceuticals, Inc.
$NRIX Nurix Therapeutics, Inc.
$EVMN Evommune, Inc.
$JNJ JOHNSON & JOHNSON
$XFOR X4 Pharmaceuticals, Inc
$PCVX Vaxcyte, Inc.
$IVVD Invivyd, Inc.
$JBIO Jade Biosciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for STEMPOINT CAPITAL LP including:
Track STEMPOINT CAPITAL LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for STEMPOINT CAPITAL LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: STEMPOINT CAPITAL LP
13F Pro is an AI hedge fund tracker and stock research platform. For STEMPOINT CAPITAL LP (SEC CIK: 1952142), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in STEMPOINT CAPITAL LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.